New Age Alpha Advisors LLC Buys New Holdings in Insulet Co. (NASDAQ:PODD)

New Age Alpha Advisors LLC bought a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 30,096 shares of the medical instruments supplier's stock, valued at approximately $7,857,000.

Several other large investors have also recently added to or reduced their stakes in PODD. Integrated Wealth Concepts LLC lifted its stake in shares of Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier's stock valued at $596,000 after purchasing an additional 42 shares during the period. Horizon Investments LLC increased its stake in Insulet by 3.1% in the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock valued at $362,000 after purchasing an additional 42 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock valued at $1,146,000 after purchasing an additional 43 shares in the last quarter. Glenmede Trust Co. NA raised its holdings in Insulet by 2.3% in the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier's stock worth $484,000 after purchasing an additional 47 shares during the period. Finally, Graypoint LLC boosted its position in shares of Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier's stock worth $243,000 after purchasing an additional 47 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. TD Cowen boosted their target price on Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, January 3rd. Piper Sandler boosted their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Citigroup increased their price objective on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a report on Friday, February 21st. Canaccord Genuity Group upped their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Raymond James reaffirmed an "outperform" rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat, Insulet has a consensus rating of "Moderate Buy" and an average target price of $292.06.

Remove Ads

Insider Activity

In other news, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares in the company, valued at $888,525. This represents a 36.10 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company's stock.

Insulet Price Performance

NASDAQ:PODD traded up $0.57 during trading hours on Tuesday, reaching $263.18. 142,848 shares of the company were exchanged, compared to its average volume of 704,961. The company has a market capitalization of $18.48 billion, a P/E ratio of 45.59, a P/E/G ratio of 3.62 and a beta of 1.29. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The business has a 50 day moving average of $271.42 and a 200 day moving average of $259.20. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. Research analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.